摘要
目的 探究仑伐替尼联合射频消融术治疗原发性肝癌患者的临床疗效及预后。方法 选择在2018年4月—2020年4月盘锦市中心医院收治的原发性肝癌患者76例,采用电脑随机分配法将患者分为单一组和联合组各38例,单一组患者行射频消融术(RFA)治疗,联合组患者给予仑伐替尼联合射频消融术治疗,比较两组肝癌患者术后6个月的临床疗效;术前及术后1个月血清中甲胎蛋白(AFP)、癌胚抗原(CEA)、肿瘤标记物(CA-199、GGT、VEGF)、肝功能水平;术后随访1年统计两组患者的生存率。结果 经治疗,联合组患者总有效率(OR)高于单一组(P<0.05);两组肝癌患者射频消融术后1个月的血液检查AFP、CEA水平均较术前降低,肝功能水平均较术前升高,差异均有统计学意义(P<0.05);联合组患者治疗后的血清肿瘤标记物水平(CA-199、GGT、VEGF)均低于单一组,两组比较差异有统计学意义(P<0.05);经随访调查,比较参与本次研究的两组患者手术治疗后1年的生存率,差异无统计学意义(P>0.05)。结论 使用仑伐替尼联合射频消融术治疗原发性肝癌,可以降低患者血清AFP、CEA水平,改善患者肝功能,提高了患者术后一年生存率,临床疗效好。
Objective To investigate the clinical efficacy and prognosis of Lenvatinib combined with radiofrequency ablation in patients with primary liver cancer.Methods A total of 76 patients with primary liver cancer admitted to Panjin central hospital from April 2018 to April 2020 were randomly divided into single group(n=38) and combined group(n=38).Patients in the single group were treated with radiofrequency ablation(RFA),and patients in the combination group were treated with Lenvatinib plus radiofrequency ablation.The clinical efficacy at 6 months after surgery,serum AFP,CEA,tumor markers(CA-199,GGT,VEGF),liver function(ALT,AST,TBIL) levels before surgery and one month after surgery were compared between the two groups.The survival rate and mortality of patients in the two groups were analyzed after 1 year of follow-up.Results After treatment,the total effective rate(OR) of combined group was significantly higher than that of single group(P 0.05).Conclusion The use of Lenvatinib combined with RFA in the treatment of patients with primary liver cancer can significantly reduce the serum AFP and CEA levels and serum tumor marker levels,improve the liver function,and improve the one-year survival rate.The clinical efficacy is good,worthy of being widely promoted.
作者
赵帅
ZHAO Shuai(Department of Oncology,Panjin Central Hospital,Panjin 12400,Liaoning Province,China)
出处
《中国实用乡村医生杂志》
2022年第7期38-41,45,共5页
Chinese Practical Journal of Rural Doctor
关键词
原发性肝癌
仑伐替尼
射频消融术
甲胎蛋白
癌胚抗原
肝功能
临床疗效
Primary Liver Cancer
Lenvatinib
Radio Frequency Ablation
Alpha-fetoprotein
Carcinoembryonic Antigen
Liver Function
Clinical Curative Effect
